BAL PHARMA LIMITED

Corporate Office
+91 80 4137 9500
info@balpharma.com
5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052, India.

Date: August 12, 2026

To
Listing Compliance Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C/2, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai-400051

Symbol: BALPHARMA

To
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai – 400001

Scrip Code: 524824

Sub: <u>Outcome of Board Meeting</u>

Ref : Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

As intimated vide our letter dated August 05, 2026, Board of directors of the Company met on Wednesday, August 12 2026 inter alia transacted the following business.

1. Considered and approved the unaudited Financial Results (Standalone and Consolidated) of the Company quarter ended on 30th June, 2026. copy of the approved financial results together with the limited review report issued by the statutory auditors of the Company with unmodified opinion is enclosed.

2. Approved the change in designation of Mr. Ravindra Kumar Kothari (DIN: 03418320) from Non-Executive Director to Whole-Time Director, designated as Executive Director, with effect from October 1, 2026, subject to the approval of the Members of the Company at the ensuing Annual General Meeting.

3. Approved the change in designation of Mr. Virupakshaya Himesh (DIN: 08554422) from Whole-Time Director to Non-Executive Director, with effect from October 1, 2026, subject to the approval of the Members of the Company at the ensuing Annual General Meeting.

4. Approved the proposal to make investment in the proposed Joint Venture entity to be incorporated in the Republic of the Philippines ("JV Entity") upto INR 09 Crores within investment limit of approval powers of the Board as prescribed under Secton 186 of the Companies act 2013 and subject to compliance with the applicable provisions of the Companies Act, 2013, the Foreign Exchange Management Act, 1999, the Overseas Investment framework, and other applicable laws and regulations.

BAL PHARMA LIMITED

Corporate Office
+91 80 4137 9500
info@balpharma.com
5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052, India.

5. The Board of Directors considered and approved the allotment of 10,00,000 (Ten Lakhs) Warrants to Mr. Shailesh Siroya, Promoter of the Company, on preferential basis, at an issue price of ₹84/- (Rupees Eighty-Four only) per Warrant, aggregating to ₹8,40,00,000/- (Rupees Eight Crores Forty Lakhs only), pursuant to the approval of the Members of the Company obtained through Postal Ballot on 08th August, 2026, and subject to applicable statutory and regulatory approvals, as may be required.

   The Company has received 25% of the issue price amounting to ₹2,10,00,000/- (Rupees Two Crores Ten Lakhs only) towards the Warrants.

   Each Warrant shall be convertible into one (1) fully paid-up Equity Share of the Company having face value of ₹10/- each, upon payment of the balance 75% of the issue price, within a period of 18 months from the date of allotment of the Warrants, in accordance with the terms of issue and applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and other applicable laws.

   The details of the allotment, including the ISIN of the underlying Equity Shares, shall be submitted to the Stock Exchanges and Depositories, as applicable.

Further details required under Regulation 30 of the SEBI LODR Regulations read with the SEBI Master Circular for items mentioned at Sl. Nos. 2 , 3 (Annexure A) and 4 (Annexure B) are enclosed.

The meeting commenced at 04.45 PM and concluded at 05.15 PM on Wednesday, August 12, 2026.

Please takes this intimation on your records

Thanking You.

For Bal Pharma Limited

Shreepada ML

Digitally signed by Shreepada ML
DN: cn=Shreepada ML, o, ou, email=sribhat111@gmail.com, c=US
Date: 2026.08.12 17:30:49 +05'30'

BAL PHARMA LTD
L85110KA1987PLC008368
BENGALURU

Shreepada ML
Company Secretary and Compliance officer
ICSI M No : A66681

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are given as under.

Annexure: A

Change of Designations of Directors: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Particulars	**Mr. Ravindra Kumar Kothari**	**Mr. Virupakshaya Himesh**
Reason for change	Change in designation from Non-Executive Director to Executive Director Subject to Members approval at ensuring AGM	Change in designation from Executive Director to Non-Executive Director Subject to Members approval at ensuring AGM
Date of appointment/re-designation	Change of Designation will effective from 01st October 2026	Change of Designation will effective from 01st October 2026
Term of appointment	Not applicable (Director already on the Board)	Not applicable (Director already on the Board)
Brief profile	Not applicable (Director already on the Board)	Not applicable (Director already on the Board)
disclosure of relationships between directors (in case of appointment of a director).	Not applicable	Not applicable
Information as required under Circular No. LIST/COMP/14/2018- 19 and NSE/CML/ 2018/02 dated June 20, 2018, issued by the BSE and NSE, respectively	The Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.	The Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

<u>Annexure: B</u>

Acquisition: Acquisition of to be incorporated Companies - Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

SL No	Particulars	Details
01	Name of the target entity, details in brief such as size, turnover etc.	Proposed New Joint Venture Entity to be incorporated in the Republic of the Philippines. <u>Parties</u> Bal Pharma Limited : ("Manufacturer"), a company incorporated under the laws of India, with its principal place of business at Bangalore, India. Hemera International Private Limited : ("Supply Chain Partner"), a company incorporated under the laws of Singapore, with its principal place of business at , Singapore. (Also referred to as Hemera Holdings Pte Limited , Holding Company / Hemera). Turnover: Nil , Size : NA *(yet to be commence business operations upon incorporation)*
02	whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length	Transactions will not fall within related party transactions
03	industry to which the entity being acquired belongs;	Registration, importation, commercialization, distribution and sale of designated pharmaceutical products

		Entity Category : Pharmaceutical
04	objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);`	To establish a structured collaboration for the registration, importation, commercialization, market penetration, distribution, and sale of designated pharmaceutical products in the Republic of the Philippines , with a strategic option for subsequent expansion into other ASEAN markets
05	brief details of any governmental or regulatory approvals required for the acquisition	Investment will be subject to applicable laws, FEMA/ODI regulations and requisite regulatory approvals of Government of India and Republic of the Philippines.
06	indicative time period for completion of the acquisition;	Depends on requisite regulatory approvals
07	consideration - whether cash consideration or share swap or any other form and details of the same	Bank transfer
08	cost of acquisition and/or the price at which the shares are acquired	Not Applicable, since it's a newly incorporating JV
09	percentage of shareholding / control acquired and / or number of shares acquired	Not Applicable, since it's a newly incorporating JV
10	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Not Applicable, since it's a newly incorporating JV
11	name of the entity, date & country of incorporation, etc.;	Republic of the Philippines. Not Applicable, since it's a newly incorporating JV
12	name of holding company of the incorporated company and relation with the listed entity;	Bal Pharma Limited, India (Manufacturer): 65.0% Hemera Holdings Pte Limited, Singapore (Supply Chain Partner) / Hemera: 35.0%

13	industry to which the entity being incorporated belongs	Pharmaceutical
14	brief background about the entity incorporated in terms of products / line of business;	physical local infrastructure will be outsourced, the JV Entity (either directly or via explicitly contracted, accredited third-party distributors and logistics providers in the Philippines) shall be responsible for holding Food and Drug Administration (FDA) registrations, securing Licenses to Operate (LTO), Product Certificates of Registration (CPR), local customs clearance, cold-chain warehousing, and domestic sales distribution
15	brief details of any governmental or regulatory approvals required for the incorporation	Republic of the Philippines.
16	nature of consideration - whether cash consideration or share swap and details of the same;	Equity Investment & Funding
17	cost of subscription / price at which the shares are subscribed	65% of Total Capital
18	percentage of shareholding / control by the listed entity and / or number of shares allotted.	65%

BAL PHARMA LIMITED

Corporate Office
+91 80 4137 9500
info@balpharma.com
5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052, India.

To
Listing Compliance Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C/2, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai-400051

Symbol: BALPHARMA

To
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai – 400001

Scrip Code: 524824

Date: August 12, 2026

Sub: Non applicability of statement of Deviation/ Variation
Ref: Regulation 32(1) of SEBI (LODR) Regulations ,2015.

Dear Sir/Madam,

With reference to the above cited subject and reference, we would like to clarify that as the Company has neither raised any funds through public issue, rights issue, preferential issue, QIP etc nor has any proceeds of the earlier issues outstanding for utilization for the quarter ended 30.06.2026, filing of statement of deviation/variation in utilization of funds raised is not applicable to the Company, for the above said quarter.

Please takes this intimation on your records

Thanking You.

For Bal Pharma Limited

BAL PHARMA LTD. CIN L85110KA1987PLC008368 BENGALURU

Shailesh Siroya
Managing Director
DIN : 00048109

BAL PHARMA LIMITED

Corporate Office

+91 80 4137 9500

info@balpharma.com

5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052, India.

Date: August 12, 2026

To
Listing Compliance Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C/2, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai-400051

Symbol: BALPHARMA

To
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai – 400001

Scrip Code: 524824

Sub: Declaration of Unmodified Opinion on Audited Financial Results for the quarter and financial year ending 30.06.2026

Dear Sir/Madam,

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare and confirm that the statutory auditors of the Company M/s. SSJNB & Co, Chartered Accountants, having membership # 00139768 have issued their limited review report with Unmodified opinion on audited Standalone and Consolidated Financial results of the Company, for the quarter and financial year ended 30th June 2026.

Please takes this intimation on your records

Thanking You.

For Bal Pharma Limited

BAL PHARMA LTD
CIN L85110KA1987PLC008368
BENGALURU

Shailesh Siroya
Managing Director
DIN : 00048109

Independent Auditor's review report on the Quarterly and year to date unaudited standalone financial results of Bal Pharma Limited pursuant to the Regulation 33 of SEBI (Listing obligations and Disclosures Requirements) Regulations, 2015, as amended

To the Board of Directors of Bal Pharma Limited

We have reviewed the accompanying statement of unaudited standalone financial results of **Bal Pharma Limited** ("the Company") for the quarter ended 30th June 2026 and the year to date from 1st April 2026 to 30th June 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and which has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial reporting "("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "*Review of Interim Financial Information performed by the Independent auditor of the Entity"* issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A Review is substantially less in scope than an audit conducted in accordance with Standards of Auditing and consequently does not enable us to obtain assurance that we have become aware of all significant matters that may be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that caused us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and disclosure Requirements) Regulations 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s. **S S J N B & Co**
Chartered Accountants
Firm registration number: 013976S

DHANPAL I SAKARIA
Digitally signed by DHANPAL I SAKARIA
Date: 2026.08.12 17:46:08 +05'30'

Dhanpal I Sakaria
Partner
Membership No: 213666
UDIN: 26213666AAQBBY4418

Place: Bengaluru
Date: 12 August 2026

BAL PHARMA LIMITED

CIN: L85110KA1987PLC008368

Regd.Office: 21-22 Bommasandra Industrial Area,Anekal Taluq,Bangalore 560 099

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2026

in Rs. Lakhs

Sl No.	Particulars	Quarter Ended			Year ended
		30-Jun-2026 Unaudited	31-Mar.2026 Audited	30-Jun-2025 Unaudited	31-Mar-2026 Audited
	Income				
I	Revenue from operations	8,842.73	8,391.76	6,563.51	31,079.70
II	Other income	45.71	-21.82	74.11	200.29
III	**Total Income - (I)+(II)**	**8,888.44**	**8,369.95**	**6,637.62**	**31,279.99**
IV	**Expenses**				
	a) Cost of materials consumed	4,847.25	4,113.65	3,602.85	16,096.74
	b) Purchase of Stock-in-trade	294.39	144.06	397.39	912.94
	c) Changes in inventories of finished goods, Stock-in-trade and work-in-progress	-25.24	-419.43	-652.18	-1,224.63
	d) Employees benefits expenses	1,692.64	1,791.82	1,466.83	6,592.40
	e) Finance costs	446.56	405.26	405.19	1,681.02
	f) Depreciation and amortization expense	278.22	304.18	251.90	1,105.90
	g) Other expenses	1,238.52	1,699.00	1,133.31	5,479.10
	Total Expense - (IV)	**8,772.34**	**8,038.54**	**6,605.30**	**30,643.48**
V	**Profit before Exceptional item and Tax (III-IV)**	**116.10**	**331.41**	**32.31**	**636.51**
VI	Exceptional items				
VII	Profit/ (Loss) before Tax (V-VI)	116.10	331.41	32.31	636.51
VIII	Less: Tax Expense				
	Current tax		-		-
	Excess/Short provision of tax written back		-		-
	Tax adjustments relating to previous year		-		-
	Deferred tax charge/ (credit)		-38.61		-38.61
		-	(38.61)	-	(38.61)
IX	**Net Profit for the period**	**116.10**	**370.02**	**32.31**	**675.12**
X	**Other Comprehensive Income(OCI)**				
	- Items that may not be reclassified to Profit or loss		43.37		43.37
	- Income tax relating to items that will not be reclassified to profit or loss		-	-	-
	Tax	**0.00**	**43.37**	**0.00**	**43.38**
XI	**Total Comprehensive income for the period (IX+X)**	**116.10**	**413.39**	**32.31**	**718.50**
XII	Paid up Equity Share Capital (Face value ₹ 10 per share)	1,592.09	1,592.09	1,592.09	1,592.09
XIII	Other Equity		8,817.82		8,817.82
XIV	Earnings per share (Face value of ₹ 10 each)				
	Basic - in ₹	0.73	2.60	0.20	4.51
	Diluted - in ₹	0.73	2.60	0.20	4.51

Notes:

1 The above standalone financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12th August 2026

2 The standalone financial results has been prepared in accordance with the Companies(Indian Accounting Standards) Rules, 2015(IND AS), prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recoganised accounting practices and policies to the extent applicable.

3 The Company has only one reportable segment namely 'Pharmaceuticals'.

4 Previous period figures have been regrouped/rearranged whereever considered necessary to conform to the period presentation.

For Bal Pharma Limited

SHAILESH
SIROYA

Digitally signed by SHAILESH SIROYA
DN: c=IN, o=Personal,
2.5.4.20=84ab941967c90d592e2ff174fc0c3d1e2a28f54cc3b61
e26f9cd3fff67d54c4a, postalCode=560020, st=Karnataka,
serialNumber=0f3b0eb66c935e3f2972d9a58c18f3254e937f84
f1fce82bf0fe2fb061000bc5, cn=SHAILESH SIROYA
Date: 2026.08.12 17:46:52 +05'30'

Shailesh Siroya
Managing Director
DIN : 00048109

Date : 12/08/2026
Place : Bangalore

S S J N B & Co
Chartered Accountants
Landline: 080-4977 7951 / 52 / 53 / 54
Email: office@ssjnb.in

Independent Auditor's review report on the Quarterly and year to date unaudited consolidated financial results of Bal Pharma Limited pursuant to the Regulation 33 of SEBI (Listing obligations and Disclosures Requirements) Regulations, 2015, as amended

To the Board of Directors of Bal Pharma Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **BAL PHARMA LIMITED ("the Parent")** and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit/(loss) after tax and total comprehensive income/loss for the quarter ended 30th June, 2026 and the year to date from 1st April 2026 to 30th June, 2026 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015, as amended.

2. This consolidated statement, which is the responsibility of the Parent's Management and which has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the consolidated statement based on our review

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The statement includes the financial results of following entities:

Lifezen Health Care Private Limited	Subsidiary
Balance Clinics LLP	Subsidiary
Bal Research Foundation	Subsidiary
Aurum Research & Analytical Solutions Private Limited	Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We reviewed the financial results of aforementioned subsidiary companies included in the consolidated audited financial results, whose financial results reflect total income (before consolidation adjustments) of ₹. 38.23 lakhs for period ended June 30, 2026 and total net loss after tax (before consolidation adjustments) of ₹. 2.33 lakhs for the period ended June 30, 2026.

For M/s**. S S J N B & Co**
Chartered Accountants
Firm registration number: 013976S

DHANPAL I SAKARIA
Digitally signed by DHANPAL I SAKARIA
Date: 2026.08.12 17:48:35 +05'30'

Dhanpal I Sakaria
Partner
Membership No: 213666
UDIN: 26213666YAKIWG7924

Place: Bengaluru
Date: 12 August 2026

BAL PHARMA LIMITED

CIN: L85110KA1987PLC008368

Regd.Office: 21-22 Bommasandra Industrial Area,Anekal Taluq,Bangalore 560 099

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2026

in Rs. Lakhs

Sl No.	Particulars	Quarter Ended			Year Ended
		30-Jun-2026 Unaudited	31-Mar.2026 Audited	30-Jun-2025 Unaudited	31 March 2026 Audited
	Income				
I	Revenue from operations	8,861.61	8,407.57	6,587.09	31,166.13
II	Other income	43.82	-23.65	72.22	192.78
III	**Total Income - (I)+(II)**	**8,905.43**	**8,383.92**	**6,659.31**	**31,358.91**
IV	**Expenses**				
	a) Cost of materials consumed	4,847.25	4,113.65	3,602.85	16,096.74
	b) Purchase of Stock-in-trade	290.73	142.03	398.47	922.66
	c) Changes in inventories of finished goods, Stock-in-trade and work-in-progress	-22.78	-422.96	(647.06)	-1,222.89
	d) Employees benefits expenses	1,706.38	1,806.55	1,480.37	6,646.48
	e) Finance costs	446.59	405.55	405.34	1,681.76
	f) Depreciation and amortization expense	278.25	305.80	252.04	1,107.93
	g) Other expenses	1,245.23	1,711.56	1,146.45	5,532.84
	Total Expense - (IV)	**8,791.66**	**8,062.19**	**6,638.46**	**30,765.53**
V	**Profit before Exceptional item and Tax (III-IV)**	**113.77**	**321.74**	**20.85**	**593.38**
VI	Exceptional items	-	-	-	-
VII	Profit/ (Loss) before Tax (V-VI)	113.77	321.74	20.85	593.38
VIII	Less: Tax Expense				
	Current tax	-			-
	Excess/Short provision of tax written back	-			-
	Tax adjustments relating to previous year	-			-
	Deferred tax charge/ (credit)	-	-38.62		-38.62
		-	(38.62)	-	(38.62)
IX	**Net Profit for the period**	**113.77**	**360.36**	**20.85**	**632.00**
	Profit / (Loss) attributable to :				
	- Equity holders of the parent company	112.35	359.35	20.06	628.36
	- Non controlling interest	1.42	1.01	0.79	3.65
X	**Other Comprehensive Income(OCI)**				
	- Items that may not be reclassified to Profit or loss	-	43.85		43.85
	- Income tax relating to items that will not be reclassified to profit or loss	-		-	-
	Income Tax	**-**	**43.85**	**-**	**43.85**
XI	**Total Comprehensive income for the period (IX+X)**	**113.77**	**404.21**	**20.85**	**675.85**
	Profit / (Loss) attributable to :				
	Equity holders of the parent company	112.35	359.35	20.06	628.36
	Non controlling interest	1.42	1.01	0.79	3.65
XII	Paid up Equity Share Capital (Face value ₹ 10 per share)	1,592.09	1,592.09	1,592.09	1,592.09
XIII	Other Equity		6,630.65		6,630.65
XIV	Earnings per share (Face value of ₹ 10 each)				
	Basic - in ₹	0.71	2.26	0.13	3.95
	Diluted - in ₹	0.71	2.26	0.13	3.95

Notes:

1 The above consolidated financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12th August 2026

2 The consolidated financial results has been prepared in accordance with the Companies(Indian Accounting Standards) Rules, 2015(IND AS), prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recoganised accounting practices and policies to the extent applicable.The audited consilidated financial results relate to Balpharma Limited, its subsidiaries (together constitute 'the group'). Joint venture and Associates and are preparedby applying IND AS 110 - " Consolidate Financial Statements ", and IND AS 28 - "Investment s in Associates & Joint ventures".

3 Previous period figures have been regrouped/rearranged whereever considered necessary to conform to the period presentation.

4 The Company has only one reportable segment namely 'Pharmaceuticals'.

For Bal Pharma Limited

SHAILESH SIROYA

Digitally signed by SHAILESH SIROYA
DN: c=IN, o=Personal,
2.5.4.20=84ab941967c90d592e2ff174fc0c3d1e2a28f54cc3b61e26f9cd3fff67d54c4a, postalCode=560020, st=Karnataka, serialNumber=0f3b0eb66c935e3f2972d9a58c18f3254e937f84f1fce82bf0fe2fb061000bc5, cn=SHAILESH SIROYA
Date: 2026.08.12 17:45:36 +05'30'

Shailesh Siroya
Managing Director
DIN : 00048109

Date : 12/08/2026
Place : Bangalore